Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial


Martin M., Holmes F. A. , Ejlertsen B., Delaloge S., Moy B. , Iwata H., ...More

LANCET ONCOLOGY, vol.18, no.12, pp.1688-1700, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.1016/s1470-2045(17)30717-9
  • Title of Journal : LANCET ONCOLOGY
  • Page Numbers: pp.1688-1700

Abstract

Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.